E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Risk of stroke by atrial fibrillation |
|
E.1.1.1 | Medical condition in easily understood language |
Increased risk for stroke by atrial fibrillation a heart arrhythmia |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10007541 |
E.1.2 | Term | Cardiac disorders |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10029205 |
E.1.2 | Term | Nervous system disorders |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10042613 |
E.1.2 | Term | Surgical and medical procedures |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
This phase 4 trial investigates whether a strategy of ongoing, long-term oral anticoagulation is superior to a strategy of antiplatelet therapy (ASA) alone in reducing the incidence of cerebral embolic events in moderate risk patients post-successful catheter ablation for atrial fibrillation. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives of the trial are the evaluation of - efficacy of rivaroxaban and ASA, respectively, in the reduction of the incidence of stroke, systemic embolism or silent cerebral infarction - safety of long-term oral anticoagulation after catheter ablation for atrial fibrillation - cost effectiveness of long-term oral anticoagulation after catheter ablation for atrial fibrillation - relationship of the atrial fibrillation burden to stroke risk |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patient must be at least one year post-successful catheter ablation(s) for atrial fibrillation without evidence of any clinically apparent arrhythmia recurrence defined as all of the following: No AF/AT/AFL on at least 24 hour Holter and an ECG (or equivalent) from 2-6 months after the last ablation, AND no AF/AT/AFL on at least 24 hour Holter and an ECG any time after 6 months after the last ablation AND no AF/AT/AFL on at least 24 hour Holter and ECG 2 months before enrolment in the study. The Holter/ECG within 2 months of enrolment may also serve as the Holter performed 6 months or later after the last ablation - see section 2.3.1 for details. 2. Patient must have a CHA2DS2-VASc risk score of 1 or more. Patients in whom female sex or vascular disease are their sole risk factor may not be enrolled. 3. Patient must be >18 years of age. 4. Patient must have non-valvular AF.
|
|
E.4 | Principal exclusion criteria |
1. Patient does not meet all of the above listed inclusion criteria. 2. Patient is unable or unwilling to provide informed consent. 3. Patient is included in another randomized clinical trial or a clinical trial requiring an insurance. 4. Patient has been on an investigational drug within 30 days of enrolment. 5. Patient has been on strong CYP3A inducers (such as rifampicin, phenytoin, phenobarbital, or carbamazepine) or strong CYP3A inhibitors (such as ketoconazole or protease inhibitors) within 4 days of enrolment. 6. Patient has creatinine clearance < 30 mL/min. 7. Patient has bleeding contra-indication to oral anticoagulation (such as bleeding diathesis, hemorrhagic disorder, significant gastrointestinal bleeding within 6 months, intracranial/intraocular/ atraumatic bleeding history, fibrinolysis within 48 hours of enrollment). 8. Patient has other contraindication to oral anticoagulation or treatment with antiplatelet agent (such as allergy). 9. Patient has a contraindication to magnetic resonance imaging (MRI) or is unlikely to tolerate due to severe claustrophobia. 10. Patients with a contraindication to implantation of an implantable loop recorder if the patient opts for loop recorder as part of the study(such as limited immunocompetence or a wound healing disorder). 11. Patient has valvular atrial fibrillation [reference AHA guidelines]. 12. Patient has a non-arrhythmic condition necessitating long-term oral anticoagulation. 13. Patient had a severe, disabling stroke within one year prior to enrollment or any stroke within 14 days of enrollment. 14. Patient with special risk factors for stroke unrelated to AF, specifically known thrombophilia/ hypercoagulability, uncontrolled hypertension (systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg within 4 days of enrollment), untreated familial hyperlipidemia, known vascular anomaly (intracranial aneurysm/ arteriovenous malformation or chronic vascular dissection), or known severe carotid disease. 15. Pregnancy or breastfeeding. 16. Women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception throughout the study. 17. Patients who are > 85 years of age. 18. Patients who are critically ill or who have a life expectancy <3 years. 19. Patients for whom the investigator believes that the trial is not in the interest of the patient. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome is a composite of stroke, systemic embolism, and covert embolic stroke as defined by assessment of cerebral magnetic resonance imaging. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Patients will be evaluated for the primary endpoint at follow up visits at 6, 12, 24 and 36 months with an MRI being performed at Baseline and 36 months for detection of covert stroke. |
|
E.5.2 | Secondary end point(s) |
1. Clinical, overt stroke 2. Incidence of one or more covert MRI stroke(s) > 15 mm3. Composite of all major and minor bleeding 4. Major bleeding only 5. Minor bleeding only 6. Intracranial hemorrhage 7. Transient ischemic attack 8. All-cause mortality 9. Net clinical benefit based on reduction in stroke/TIA rate compared to major bleeding events 10. Occurrence of non-primary endpoint MRI changes from baseline to final scan 11. Neuropsychological testing 12. Quality of life assessment 13. Cost utilization and cost effectiveness analysis |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Patients will be evaluated for endpoints at follow up visits at 6, 12, 24 and 36 months with an MRI being performed at baseline and 36 months for detection of covert stroke. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 17 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 28 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
China |
Israel |
Belgium |
Germany |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |